BiotechTube

BMN 307

Phase 1/2Active
2 views this week 0 watching💤 Quiet
Interest: 33/100
33
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Phenylketonuria (PKU)

Conditions

Phenylketonuria (PKU)

Trial Timeline

Sep 24, 2020 → Dec 1, 2027

NCT ID
NCT04480567

About BMN 307

BMN 307 is a phase 1/2 stage product being developed by BioMarin Pharmaceutical for Phenylketonuria (PKU). The current trial status is active. This product is registered under clinical trial identifier NCT04480567. Target conditions include Phenylketonuria (PKU).

What happened to similar drugs?

7 of 20 similar drugs in Phenylketonuria (PKU) were approved

Approved (7) Terminated (1) Active (12)
❌SYNB1934v1 + PlaceboSynlogicPhase 3
🔄Kuvan®MerckPhase 3
✅Kuvan®MerckApproved
🔄Sapropterin dihydrochloride + PlaceboBioMarin PharmaceuticalPhase 3
🔄BMN165 20mg/day + BMN165 40mg/day + PlaceboBioMarin PharmaceuticalPhase 3
🔄sapropterin dihydrochlorideBioMarin PharmaceuticalPhase 3
✅saproterin dihydrochlorideBioMarin PharmaceuticalApproved

Hype Score Breakdown

Clinical
9
Activity
12
Company
12
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT04480567Phase 1/2Active

Competing Products

20 competing products in Phenylketonuria (PKU)

See all competitors
ProductCompanyStageHype Score
mRNA-3210ModernaPhase 2
0
SYNB1934v1 + PlaceboSynlogicPhase 3
22
SYNB1618 + PlaceboSynlogicPhase 1/2
22
SYNB1618 + SYNB1934SynlogicPhase 2
25
Kuvan®MerckPhase 3
40
Kuvan®MerckApproved
43
SAR444836SanofiPhase 1/2
36
KuvanBioMarin PharmaceuticalPre-clinical
15
rAvPAL-PEGBioMarin PharmaceuticalPhase 2
32
rAvPAL-PEGBioMarin PharmaceuticalPhase 2
32
Sapropterin (Kuvan)BioMarin PharmaceuticalPre-clinical
23
BMN 165 (rAvPAL-PEG)BioMarin PharmaceuticalPhase 2
32
SapropterinBioMarin PharmaceuticalPre-clinical
23
Sapropterin dihydrochloride + PlaceboBioMarin PharmaceuticalPhase 3
37
BMN165 20mg/day + BMN165 40mg/day + PlaceboBioMarin PharmaceuticalPhase 3
37
sapropterin dihydrochlorideBioMarin PharmaceuticalPhase 3
37
saproterin dihydrochlorideBioMarin PharmaceuticalApproved
40
sapropterin dihydrochloride + Moxifloxacin + Moxifloxacin placeboBioMarin PharmaceuticalPhase 1
26
PegvaliaseBioMarin PharmaceuticalPre-clinical
30
PegvaliaseBioMarin PharmaceuticalPre-clinical
23